source
- Roivant's brepocitinib shows strong Phase 3 results, paving way for uveitis indicationRoivant subsidiary Priovant Therapeutics announced positive Phase 3 data for its anti‑inflammatory drug brepocitinib in patients with non‑infectious uveitis, an eye disease that can cause blindness…
- Gilead’s emvistegrast shows superior response to placebo in Phase 2 ulcerative colitis trialGilead Sciences reported that its investigational oral drug emvistegrast achieved a higher clinical response rate than placebo in a Phase 2 study of ulcerative colitis. The trial enrolled 238 patie…